

Accepted Manuscript

Initial Risk Assessment as part of the Quality by Design in peptide drug containing formulation development

E. Pallagi, R. Ismail, T.L. Paál, I. Csóka



PII: S0928-0987(18)30301-4

DOI: doi:[10.1016/j.ejps.2018.07.003](https://doi.org/10.1016/j.ejps.2018.07.003)

Reference: PHASCI 4579

To appear in: *European Journal of Pharmaceutical Sciences*

Received date: 19 February 2018

Revised date: 2 July 2018

Accepted date: 2 July 2018

Please cite this article as: E. Pallagi, R. Ismail, T.L. Paál, I. Csóka , Initial Risk Assessment as part of the Quality by Design in peptide drug containing formulation development. Phasci (2018), doi:[10.1016/j.ejps.2018.07.003](https://doi.org/10.1016/j.ejps.2018.07.003)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Initial Risk Assessment as part of the Quality by Design in peptide drug containing formulation development

E. Pallagi¹, R. Ismail¹, T. L. Paál¹, I. Csóka¹

¹ University of Szeged, Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, H-6720, Szeged, Eötvös u. 6, Hungary

Corresponding author:

Dr. Edina Pallagi PhD
University of Szeged, Faculty of Pharmacy
Institute of Pharmaceutical Technology and Regulatory Affairs, H-6720, Szeged, Eötvös u. 6,
Hungary
email: edina.pallagi@pharm.u-szeged.hu, edinapallagi@hotmail.com
Tel: +36-62-546-115
Mobile: +36-70-630-4767
Fax: +36-62-545-571

Download English Version:

<https://daneshyari.com/en/article/8510976>

Download Persian Version:

<https://daneshyari.com/article/8510976>

[Daneshyari.com](https://daneshyari.com)